Pain‐relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice

Clinical trials have demonstrated the efficacy and safety of the capsaicin 8% patch in patients with peripheral neuropathic pain (PNP); however, few studies have assessed this treatment in a clinical practice.

• Publication year

  2018

• Venue

  European Journal of Pain

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ejp.1180PMID 29388284PMCID 5947653
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study

  2017influential reference
• Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study.

  2017cited by this paper
• Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study

  2016cited by this paper
• Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain

  2015influential reference
• Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.

  2015influential reference
• Qutenza (Capsaicin) 8% Patch Onset and Duration of Response and Effects of Multiple Treatments in Neuropathic Pain Patients

  2014cited by this paper
• Pregabalin abuse and dependence in Germany: results from a database query

  2013cited by this paper
• Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study

  2013cited by this paper
• Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study

  2013cited by this paper
• Substance misuse of gabapentin.

  2012cited by this paper
• A Randomized, Double-Blind, Controlled Study of NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-Associated Distal Sensory Polyneuropathy

  2012influential reference
• Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch

  2011cited by this paper
• Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management

  2011cited by this paper
• A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.

  2011influential reference
• A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers.

  2010cited by this paper
• The evidence for pharmacological treatment of neuropathic pain

  2010influential reference
• EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision

  2010cited by this paper
• NEUROPATHIC PAIN: REDEFINITION AND A GRADING SYSTEM FOR CLINICAL AND RESEARCH PURPOSES

  2009cited by this paper
• NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.

  2008influential reference
• Neuropathic pain

  2008cited by this paper
• Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy

  2008cited by this paper
• Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D

  2005influential reference
• Assessing the clinical significance of change scores recorded on subjective outcome measures.

  2004cited by this paper
• Clinical importance of changes in chronic pain intensity measured on an 11‐point numerical pain rating scale

  2001cited by this paper
• EQ-SD: a measure of health status from the EuroQol Group

  2001cited by this paper
• Vanilloid (Capsaicin) receptors and mechanisms.

  1999cited by this paper

• Topical analgesics for neuropathic pain: An Evidence-Informed guide for the practicing clinician.

  2025cites this paper
• Progressive Response of Repeated Treatment with High-Concentration (179 mg) Capsaicin Patch in Peripheral Neuropathic Pain After Surgical or Traumatic Nerve Injury: Findings from the 12-Month German CASPAR Registry Study

  2025cites this paper
• Narrative review of the efficacy and safety of the high-concentration (179mg) capsaicin patch in peripheral neuropathic pain with recommendations for clinical practice and future research

  2025cites this paper
• Real-world 12-month outcomes of repeated high-concentration capsaicin patch in chemotherapy-induced peripheral neuropathy: results from the CASPAR study

  2025cites this paper
• Making Sense of Topical Pain Relief Options: Comparing Topical Analgesics in Efficacy and Safety

  2024cites this paper
• Topical capsaicin 8% patch in peripheral neuropathic pain: Efficacy and quality of life

  2023influential citation
• Evaluation of 8% Capsaicin Patches in Chemotherapy-Induced Peripheral Neuropathy: A Retrospective Study in a Comprehensive Cancer Center

  2023cites this paper
• Capsaicin 8% Dermal Patch for Neuropathic Pain in a Pain Unit.

  2022cites this paper
• Capsaicin 8% for Peripheral Neuropathic Pain Treatment: A Retrospective Cohort Study.

  2022cites this paper
• Nutzen und Wirtschaftlichkeit der Topischen Behandlung Peripherer Neuropathischer Schmerzen mit dem Capsaicin-Pflaster Qutenza – ein Literaturüberblick

  2022cites this paper
• The role of the capsaicin 8% patch in the treatment of painful diabetic peripheral neuropathy.

  2022cites this paper
• Capsaicin 8% Patch for Alternative Therapy of Painful Diabetic Peripheral Neuropathy

  2021cites this paper
• The efficacy and safety profile of capsaicin 8% patch versus 5% Lidocaine patch in patients with diabetic peripheral neuropathic pain: a randomized, placebo-controlled study of south Asian male patients

  2021cites this paper
• Post Laparoscopy Neuropathic Pain Treated by Capsaicin 8% Dermal Patch

  2021cites this paper
• Progressive Response to Repeat Application of Capsaicin 179 mg (8% w/w) Cutaneous Patch in Peripheral Neuropathic Pain: Comprehensive New Analysis and Clinical Implications

  2021cites this paper
• Capsaicin 179-mg cutaneous patch in the treatment of post-surgical neuropathic pain: a scoping review of current evidence and place in therapy

  2021cites this paper
• Expert Opinion: Exploring the Effectiveness and Tolerability of Capsaicin 179 mg Cutaneous Patch and Pregabalin in the Treatment of Peripheral Neuropathic Pain

  2020cites this paper
• Using transdermal patches to treat neuropathic pain.

  2020cites this paper
• Capsaicin 8% dermal patch in clinical practice: an expert opinion.

  2020cites this paper
• Topical Capsaicin for the Treatment of Neuropathic Pain.

  2020cites this paper
• The use of high dose topical capsaicin in the management of peripheral neuropathy: narrative review and local experience

  2020cites this paper
• Solution dynamics of the natural bioactive molecule capsaicin: a relaxation study

  2019cites this paper
• QAPSA: post-marketing surveillance of capsaicin 8% patch for long-term use in patients with peripheral neuropathic pain in France

  2019cites this paper
• Capsaicin 8% dermal patch in peripheral neuropathic pain: a profile of its use

  2019cites this paper
• Patients’ Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice

  2019cites this paper
• Langzeiteffektivität topisch applizierter Analgetika

  2019cites this paper
• Novel insights on the management of pain: highlights from the 'Science of Relief' meeting.

  2019cites this paper
• Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain

  2018cites this paper